Mesenchymal stem cells (MSCs) are making waves in cell therapy, thanks to their ability to regenerate tissue and modulate the immune system without triggering severe reactions—a stark contrast to therapies like CAR T cells. Yet, their clinical use has been hampered by inconsistent production and the need for continuous tissue donations. Now, the Cymerus™ platform from the University of Wisconsin–Madison and Cynata Therapeutics is changing the game. By harnessing induced pluripotent stem cells (iPSCs), this breakthrough method allows for scalable, reproducible MSC manufacturing—paving the way for next-gen treatments for conditions like osteoarthritis.
https://www.impactlab.com/2025/05/15/advancing-msc-based-therapies-overcoming-manufacturing-barriers-with-the-cymerus-platform/
https://x.com/ThomasFrey/status/1923930325698195875
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.003(1.27%) |
Mkt cap ! $45.19M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 21.0¢ | 20.0¢ | $21.59K | 103.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8632 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 31699 | 2 |
View Market Depth
| Last trade - 12.44pm 21/08/2025 (20 minute delay) ? |
| CYP (ASX) Chart |